Search

Search Constraints

You searched for: Author/Creator Flaherty, Keith

Search Results

1. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Issue 1 (December 2017)

2. Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Issue 3 (12th March 2019)

3. CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. (5th November 2018)

4. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. (December 2018)

5. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Issue 3 (March 2020)

6. CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. (11th November 2019)

7. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab‐Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. (4th December 2017)

8. 228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy. (9th November 2020)

9. 228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy. (9th November 2020)

10. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. (4th November 2015)